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Purpose: Techniques designed to identify differentially ex-
pressed genes (DEGs) in tumors have become important in 
modern pathology. Genefishing techniqueTM using the anne-
aling control primer (ACP) system has recently been devel-
oped to screen for DEG transcripts. We tried to identify DEGs 
involved in papillary thyroid cancer (PTC) by using Gene-
fishing techniqueTM. Materials and Methods: We utilized a 
new differential display method, designated with Genefishing 
techniqueTM, to analyze DEGs in 21 cases of PTCs. Results: 
Comparing the gene expression profiles between PTC and 
normal thyroid, we detected 17 genes that were differentially 
expressed in PTCs and performed cloning with sequencing in 
10 genes. We confirmed the expression patterns of 2 DEGs 
by RT-PCR assay and identified the same results in 17 out 
of 21 (81%) PTCs. The 2 DEGs over-expressed in PTCs were 
identified as DC-STAMP and type I collagen A1. They are novel 
genes identified first in PTCs. Conclusion: We confirmed 2 
DEGs in PTCs as DC-STAMP and type I collagen A1 by using 
Genefishing techniqueTM. Although the detailed functions of 
those 2 genes and their products remain to be determined, the 
genes will provide insights into mechanisms of carcinogenesis 
or tumor progression in PTCs.
Key Words: Papillary thyroid cancer, differentially expressed 
genes, dendritic cell-specific transmembrane protein, type I 
collagen A1
INTRODUCTION
Papillary thyroid cancer (PTC) is the most com-
mon thyroid malignancy.1 The biological behavior 
of PTC varies widely, from indolent micro-car-
cinomas to invasive tumors that can metastasize. 
Although the etiology of PTC is not well defined, 
a strong association with exposure to ionizing radia-
tion exists in a minority of cases.2 Many attempts 
have been made to identify markers for thyroid 
carcinoma that can distinguish between benign 
and malignant lesions. However, most of them 
were proven to be not specific enough, including 
Galectin-3, BRAF, Met, hTERT, and HBME-1.3-7
Techniques designed to identify differentially 
expressed genes (DEGs) in tumors have become 
pivotal in modern pathology. Genefishing tech-
niqueTM using the annealing control primer (ACP) 
system has recently been developed by Hwang et 
al. to screen for DEG transcripts.8 It uses primers 
that anneal specifically to the template and allows 
only genuine products to be amplified, thus elimi-
nating false-positive results. 
We adapted the ACP system for the identi-
fication of DEGs involved in PTCs. Differential 
display was performed by using kits which incor-
porated an ACP. We confirmed the expression 
patterns of 10 DEGs, and quantified their expres-
sion by RT-PCR. These results suggest that this 
new PCR-based technique is a very useful tool for 
identification of novel genes differentially ex-
pressed in PTCs. 
MATERIALS AND METHODS
Patient population
Twenty-one patients diagnosed with PTC were 
included in this study. The frozen tissues from 
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patients were used for RNA isolation. And the 
frozen tissue from only one subject was used for 
the differential display analysis. 
All PTCs were analyzed according to various 
clinical-pathological parameters. Clinical staging 
of PTC was classified according to the Tumor 
Node Metastasis (TNM) classification of the Inter-
national Union Against Cancer (UICC). 
GeneFishingTM reverse transcription-polymerase 
chain reaction
First-strand cDNA synthesis
Total RNAs extracted from frozen samples were 
used for the synthesis of first-strand cDNAs by 
reverse transcriptase. Reverse transcription was 
performed for 1.5 hours at 42ºC in a final reaction 
volume of 20 μL containing 3 μg of the purified 
total RNA, 4 μL of 5' reaction buffer (Promega, 
Madison, WI, USA), 5 μL of dNTPs (2 mM each), 
2 μL of 10 μM dT-ACP1 (5'-CGTGAATGCTGCGA 
CTACGATIIIIIT(18)-3'), 0.5 μL of RNasinⓇ RNase 
Inhibitor (40 U/μL; Promega), and 1 μL of Moloney 
murine leukemia virus reverse transcriptase (200 
U/μL; Promega). First-strand cDNAs were diluted 
by the addition of 80 μL of ultra-purified water for 
the GeneFishingTM PCR and stored at -20ºC until 
use.
ACP (Annealing Control Primer)-based GeneFishingTM 
PCR
DEGs were screened by ACP-based PCR method 
using the GeneFishingTM DEG kits (Seegene, 
Seoul, South Korea). Briefly, second-strand cDNA 
was synthesized at 50ºC during one cycle of first- 
stage PCR in a final reaction volume of 20 μL con-
taining 3 - 5 μL (about 50 ng) of diluted first-strand 
cDNA, 1 μL of dT-ACP2 (10 μM), 1 μL of 10 μM 
arbitrary ACP, and 10 μL of 2 × Master Mix 
(Seegene, Seoul, South Korea). The PCR protocol 
for second-strand synthesis was one cycle at 94ºC 
for 1 minute, followed by 50ºC for 3 minutes, and 
72ºC for 1 minute. After second-strand DNA syn-
thesis was completed, the second-stage PCR 
amplification protocol was 40 cycles of 94ºC for 40 
seconds, followed by 65ºC for 40 seconds, 72ºC for 
40 seconds and 5 minutes final extension at 72ºC. 
The amplified PCR products were separated in 2% 
agarose gel and stained with ethidium bromide. 
Cloning and sequencing
The differentially expressed bands were ex-
tracted from the gel by using the GENCLEANⓇ 
II Kit (Q-BIO gene, Carlsbad, CA, USA), and 
directly cloned into a TOPO TA cloning vector 
(Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer's instructions. The cloned plasmids 
were sequenced with ABI PRISMⓇ 3100 Genetic 
Analyzer (Applied Biosystems, Foster City, CA, 
USA). 
The DNA sequence of each gene was confirmed 
by comparison with sequences in GenBank (NIH, 
MD, USA). The primer sequence of each gene was 
designed using the PRIMER 3 program (MIT, 
Boston, MA, USA). The synthesis of primers was 
performed by Bioneer Company.
RT-PCR confirmation
The differential expression of DEGs was confir-
med by RT-PCR using each gene specific primer 
pair. The first-strand cDNA was normalized by 
the human beta-actin gene. The normalized cDNA 
was used as a template. The PCR reaction was 
conducted in a final reaction volume of 20 μL con-
taining 2 - 4 μL (about 50 ng) of diluted first- 
strand cDNA, 1 μL of primer 5 (10 μM), 1 μL of 
primer 3 (10 μM), and 10 μL of 2 × Master Mix 
(Seegene, Seoul, South Korea). The PCR am-
plification protocol was an initial 3 minutes 
denaturation at 94ºC, followed by 20 - 25 cycles of 
94ºC for 40 seconds, 60ºC for 40 seconds, 72ºC for 
40 seconds, and a 5 minutes final extension at 
72ºC. The amplified PCR products were separated 
in 2% agarose gel and stained with ethidium 
bromide.
RESULTS
Clinicopathologic features
The ages of 21 patients (2 men and 19 women) 
ranged between 18 and 66 years (mean age, 46 
years). Clinical staging according to the TNM 
classification showed stage I in 3, stage II in 9, 
stage III in 8, and stage IVA in 1 patient(s). His-
tologically, 19 cases showed classic findings of 
Ki-Young Lee, et al.62
Yonsei Med J Vol. 50, No. 1, 2009
Table 1. Clinicopathologic Features of Twenty-One Papillary Thyroid Cancers
Patient no. Stage Age/Sex  (yrs) (M:F) Subtype Tumor size (cm)
Extrathyroidal 
extension LN metastases
1 II 37/F Classic 2 + +
2 I 43/F Classic 1 - -
3 I 52/F Classic 1 + -
4 III 49/F Classic 4 + +
5 III 46/M Classic 4 + +
6 III 58/F Classic 3 + +
7 II 25/F Classic 3 + -
8 IVA 47/F Classic 4 + +
9 II 52/F Classic 1 + -
10 II 66/F Follicular 2 + -
11 II 29/F Classic 2 + -
12 III 61/M Classic 2 + +
13 II 37/F Classic 3 + +
14 I 57/F Follicular 3 - -
15 III 50/F Classic 2 + +
18 III 45/F Classic 5 + +
17 II 46/F Classic 1 + -
18 II 45/F Classic 1 + -
19 II 49/F Classic 2 + -
20 III 18/F Classic 3 + +
21 III 55/F Classic 5 + +
M, male; F, female; LN, lymph node.
PTC, and 2 cases (No. 10 and 14) were follicular 
variant of PTC (Table 1). 
Differentially expressed genes (DEGs) in papillary 
thyroid cancers
To identify genes that are specifically or pre-
dominantly expressed in PTC, we compared the 
mRNA expression profiles of PTC with those of 
normal thyroid. To do this, the mRNAs from both 
samples were extracted and subjected to ACP RT 
-PCR analysis using a combination of 120 arbi-
trary primers and 2 anchored oligo(dT) primers 
(dT-ACP 1 and dT-ACP 2). The expression levels 
of certain mRNAs were compared between 
normal thyroid tissue and PTC tissue of same 
patients. The expression levels of certain mRNAs 
were either lower or higher in PTCs than in the 
normal thyroid. The analysis generated about 800 
amplicons. There are 8 genes over-expressed in 
normal thyroid and 9 genes over-expressed in 
PTC (Fig. 1). Among the 17 DEGs differentially 
expressed, 10 DEGs isolated were cloned, sequ-
enced, and searched with GeneBank (Fig. 2). These 
differential display patterns between normal 
thyroid and PTC, as assessed by ACP RT-PCR, 
were very reproducible.
Fig. 1. GeneFishingTM DEG screening results.
There are 8 genes overexpressed in normal 
thyroid (arrowhead) and nine genes over-
expressed in PTC (arrow). 1. normal, 2. PTC.
DEG, differentially expressed gene; PTC, 
papillary thyroid cancer.
Fig. 2. The mRNAs of the 10 DEGs showing
distinct results were extracted, amplified 
using the TOPOⓇ TA Cloning kit and were 
sequenced. DEGs, differentially expressed 
genes; TA, Taq-amplified.
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Detection of gene from cloning and sequencing
The mRNAs of the DEGs showing distinct results 
were extracted, amplified using the TOPO TA 
Cloning kit (Invitrogen, K4500-01, CA, USA) and 
were sequenced.
The DNA sequence of each gene was confirmed 
by comparison with sequences in GenBank (NIH, 
MD, USA). Table 2 shows 10 DEGs accessed by 
GeneBank and their homologies.
Confirmation of ACP observations by RT-PCR
To confirm the efficacy of the ACP system, the 
differential expression of DEG was confirmed by 
RT-PCR using each gene specific primer pair. The 
DEG3 and DEG14 were subjected to confirmation 
with RT-PCR, because they were distinctively high 
in tumor tissue. The primers which we designed 
are shown in Fig. 3. With RT-PCR, we confirmed 
ACP observation, as shown in Fig. 4. Addition-
ally, we analyzed 21 PTC samples by RT-PCR for 
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Table 2. The 10 DEGs Isolated were Cloned, Sequenced, and Searched with GeneBank. DEGs, Differentially Expressed Genes
DEG no.
Genebank 
 Sequence homology search
Accession no.
DEG1 NM_014624 • Homo sapiens S100 calcium binding protein A6 (calcyclin) (S100A6) 
DEG2 NM_004753 • Homo sapiens dehydrogenase/reductase (SDR family) member 3 (DHRS3)
DEG3 NM_030788 • Homo sapiens transmembrane 7 superfamily member 4 (TM7SF4)
DEG4 BC034545 • Homo sapiens PRP8 pre-mRNA processing factor 8 homolog (yeast) 
AC021016 • Homo sapiens BAC clone RP11-378A13 from 2, complete sequence 
AC012353 • Homo sapiens BAC clone RP11-82P18 from 2, complete sequence 
DEG7 BC007097 • Homo sapiens tissue inhibitor of metalloproteinase 1 
DEG10 AC023509 •Homo sapiens 12 BAC RP11-793H13 (Roswell Park Cancer Institute Human BAC Library) 
complete sequence 
BX484999 •DKFZp686F08245_s1 686 (synonym: hlcc3) Homo sapiens cDNA clone DKFZp686F08245 3’
DEG13 HS568C11 • Human DNA sequence from clone RP4-568C11 on chromosome 20p11.21-11.23 Contains 
the CST7 gene for cystatin F 
AK057704 • Homo sapiens cDNA FLJ33142 fis, clone UTERU1000192 
HUMERRNA • Human endogenous retrovirus envelope region (PL1). 
DEG14 NM_000088 • Homo sapiens collagen, type I, alpha 1 (COL1A1)
DEG15 NM_000088 • Homo sapiens collagen, type I, alpha 1 (COL1A1) 
DEG16 HUMUG2A • Human small nuclear RNA U2 gene 
RT-PCR Primer set
DEG3 (470 bp)
D3-5
AGC CGC TGG GAG AAG TCA A
D3-3
GCT TGT GAG GCT GTG GTA GAG
DEG14 (590 bp)
D14-5
AGA CCT GCG TGT ACC CCA CT
D14-3
GGT TCA GTT TGG GTT GCT TGT
Human β-actin (510 bp)
hβ-actin 5
GAC TAT GAC TTA GTT GCG TTA
Hβ-actin 3
GCC TTC ATA CAT CTC AAG TTG
Fig. 3. RT-PCR primer sets of DEG3 and DEG14. RT-PCR,
reverse transcriptase-polymerase chain reaction; DEG, 
differentially expressed gene.
Fig. 4. The DEG3 and DEG14 were subjected to confir-
mation with RT-PCR and confirmed ACP observation. 
RT-PCR, reverse transcriptase-polymerase chain reaction; 
ACP, annealing control primer.
DEG3 and DEG14, and observed up-regulated ex-
pression in 17 out of 21 (81%) tumors (Fig. 5). 
Overexpressed genes not previously associated 
with PTC
Genes that we found to be over-expressed in 
PTCs have previously been associated with other 
cells, tumor cells, stromal cells, or cell cycle con-
trol. Examples include type 1 Collagen, A1 
(COL1A1),9,10 which has frequently been shown to 
be over-expressed, as determined by quantitative 
Fig. 5. In 21 PTC samples by RT-PCR, 
DEG3 and DEG14 were observed to be 
up-regulated in most tumors. Bothe DEGs 
in 2 cases of follicular subtype (No. 10 and
No. 14) were not up-regulated. PTC, papil-
lary thyroid cancer; RT-PCR, reverse tran-
scriptase-polymerase chain reaction; DEG, 
differentially expressed gene.
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RT-PCR. Although COL1A1 expression has been 
demonstrated in tumor cells and tumor-associated 
stromal cells in multiple cancers,11 COL1A1 has 
been reported to be elevated in tumor endothe-
lium, compared with normal endothelium,12 sug-
gesting that they play an important role in angio-
genesis and formation of desmoplasia in PTC. 
Dendritic cell-specific transmembrane protein 
(DC-STAMP)13-17 is preferentially expressed by DC 
in vitro and ex vivo. DC-STAMP was originally 
isolated from a cDNA library of human monocyte- 
derived dendritic cells and encodes a protein with 
putative 7-transmembrane domains. 
 
DISCUSSION
Thyroid cancer is the most common endocrine 
malignancy, and the biological behavior of PTC 
varies widely. Although the etiology of PTC is not 
well defined, a strong association with exposure 
to ionizing radiation exists in a minority of cases.2 
Also, it has been suggested the involvement of 
specific genes, including tumor suppressor genes, 
oncogenes, apoptosis-associated genes and other 
predisposing genes. However, genes, signaling 
pathways, and other basic mechanisms are cur-
rently not well characterized. Another issue is the 
diagnostic and prognostic biomarkers of PTC. The 
classical oncogenic alterations commonly seen in 
thyroid cancer include Ras mutations,18,19 RET/ 
PTC rearrangements,20-22 and BRAF mutation.4 The 
recently discovered activating mutation in BRAF 
represents the most common genetic alteration in 
thyroid cancer. Most of the genetic alterations in 
thyroid cancer exert their oncogenic actions through 
the activation of the MAP kinase pathway. When 
constitutively activated, the MAP kinase pathway 
leads to tumorigenesis.23,24 The discovery of the 
BRAF mutation in PTC represents one of the most 
important recent achievement in thyroid cancer 
research and is of significant clinical potential. 
Many attempts have been made to identify markers 
for thyroid carcinoma that can distinguish between 
benign and malignant lesions. Most have been 
proven to be not specific enough, including 
Galectin-3, BRAF, Met, and Cyclin-D1.3,4,7,25 
Techniques designed to identify DEGs in tumors 
have become critical in modern pathology. Dif-
ferential display, a screening method described by 
Liang et al.,26 requires PCR using short arbitrary 
primers. Although this method is simple, rapid, 
and requires only small amounts of total RNA, 
many investigators have experienced signifi-
cantly high false-positive rates and poor repro-
ducibility of results,27,28 because of non-specific 
annealing by short arbitrary primers. The use of 
longer primers (18 - 20 bp) makes it possible to 
increase the annealing temperature to 60°C after 
1 - 4 initial cycles at 40 - 45°C.29 However, the 
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additional tail sequences of longer primers are 
involved in nonspecific annealing to the cDNA 
template during PCR cycles at low annealing 
temperatures.8 Genefishing techniqueTM using the 
ACP system, has recently been developed by 
Hwang et al.8 to screen for DEG transcripts. It 
uses primers that anneal specifically to the tem-
plate and allows only genuine products to be 
amplified, thus eliminating false-positive results. 
In the present study, we used the ACP system for 
the identification of DEGs involved in PTC tumo-
rigenesis, and confirmed the expression patterns 
of 10 DEGs and quantified their expression by RT- 
PCR. We found type 1 Collagen A1, DC-STAMP 
and other novel genes in PTCs.
Collagen type 1 (COL1A1)9,10 has frequently 
been found to be over-expressed, as determined 
by quantitative RT-PCR in 17 out of 21 (81%) PTCs. 
Although COL1A1 expression was demonstrated 
in tumor cells and tumor-associated stromal cells 
in multiple cancers,11 COL1A1 was reported to be 
elevated in tumor endothelium, compared with 
normal endothelium,12 suggesting that they play 
an important role in angiogenesis and formation 
of desmoplasia. Since a dense demoplastic reaction 
and matrix remodeling induced by tumor are 
prominent components of most PTCs, over-ex-
pression of COL1A1 can be associated with inva-
sive process.
Dendritic cell-specific transmembrane protein 
(DC-STAMP)13-16 is preferentially expressed by DC 
in vitro and ex vivo. DC-STAMP was originally 
isolated from a cDNA library of human monocyte- 
derived dendritic cells and encodes a protein with 
putative seven-transmembrane domains. The 
pathologic significance of this novel gene in PTC 
can not currently be explained. Further investiga-
tions using immunohistochemistry or in situ hybri-
dization is mandatory for this interesting mole-
cule in PTC.
The expression of calcyclin (DEG1) was studied 
for in various benign and malignant thyroid 
lesions by Nagy et al.30 However, its expression in 
PTC still remains to be evaluated in large series 
of PTCs.
The other genes differentially expressed in PTCs 
include SDR member 3 (DEG2),31 PRP8 (DEG4), 
TIMP1 (DEG7),32 and Cystatin F (DEG13). They have 
not been studied in PTCs so far, and need further 
evaluation.
With extensive study for the differential gene 
expression patterns of PTCs using GeneFishingTM 
with ACP primers, we conclude as follows;
1) The ACP-based strategy which we used to 
identify DEGs in PTCs is easy, and produces 
no false positive and yields reproducible re-
sults.
2) With this method, we detected 17 genes that 
are differentially expressed in PTCs and cloned 
with sequences of 10 genes.
3) We confirmed the expression patterns of 2 
DEGs by RT-PCR assay, and identified con-
sistent results in 81% (17/21) of PTCs.
4) The two DEGs overexpressed in PTCs were 
confirmed to be DC-STAMP and type I 
collagen A1. They are novel genes, identified 
first in PTCs. 
5) Although the detailed functions of these two 
genes and their products remain to be deter-
mined, the genes presently identified are 
expected to provide insights into mechanisms 
of carcinogenesis or tumor progression in 
PTCs. 
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